Alnylam seeks MHRA approval to start ALN-AAT02 phase 1/2 trial

Alnylam seeks MHRA approval to start ALN-AAT02 phase 1/2 trial

Submitted by admin on October 4, 2018 - 6:55pm
Source: 
Pharmaceutical Business Review
News Tags: 
Alnylam
RNAi
ALN-AAT02
MHRA
UK
Headline: 
Alnylam seeks MHRA approval to start ALN-AAT02 phase 1/2 trial
snippet: 

ALN-AAT02 is Alnylam’s first investigational RNAi therapeutic utilizing the Company’s enhanced stabilization chemistry plus (ESC+) GalNAc-conjugate technology.

Do Not Allow Advertisers to Use My Personal information